Advanced search×

Recombinant factor IX for clinical and research use.

Paul E Monahan and Jorge Di Paola

Semin Thromb Hemost 36(5):498-509 (2010) PMID 20632248

The last significant advance in the therapy of hemophilia B was the introduction of recombinant factor IX (FIX), ensuring an advanced level of safety from potential infectious contaminants of plasma-derived clotting factors. Since that time, recombinant DNA techniques have been applied in research to elucidate the role of FIX and its functional domains within coagulation. At the same time, recombinant DNA technology has been applied to engineer an expanding spectrum of novel FIX therapies that are now being translating into clinical trials. The experience with the existing recombinant FIX product is reviewed with a focus on the novel products and the potential to improve the quality of life for individuals with hemophilia B.

DOI: 10.1055/s-0030-1255444
Version: za2963e q8zad q8zb5 q8zc2 q8zd5 q8zef q8zf2 q8zg7
Buy PDF

Similar articles you may find interesting…

  1. Trends in the medical management of patients with heart failure.
    Samuel W Joffe, Matthew Dewolf, and Robert J Goldberg

    J Clin Med Res 5(3):194-204 (2013) PMID 23671545

    We reviewed the medical records of 9,748 residents of the Worcester, MA, metropolitan area who were hospitalized with ADHF at all 11 central Massachusetts medical centers in 1995, 2000, 2002, and 2004. Between 1995 and 2004, respectively, the prescription upon hospital discharge of b...
    PDF not found
  2. Assessment of 126,913 inguinal hernia repairs in the Emilia-Romagna region of Italy: analysis of 10 years.
    L Ansaloni, F Coccolini, and R M Melotti

    Hernia (2013) PMID 23677326

    126,913 inguinal hernioplasty procedures were performed. The annual rate was on average 34 per 10,000 inhabitants. An increase of the case mix complexity and relevant changes in procedure technique were recorded. From multivariate analysis, the following independent factors related to a hospitalizat...
    Buy PDF
  3. Comparative Effectiveness Research in Cancer Genomics and Precision Medicine: Current Landscape and Future Prospects.
    Naoko I Simonds, Muin J Khoury, and Andrew N Freedman

    J Natl Cancer Inst (2013) PMID 23661804

    A major promise of genomic research is information that can transform health care and public health through earlier diagnosis, more effective prevention and treatment of disease, and avoidance of drug side effects. Although there is interest in the early adoption of emerging genomic...
    Buy PDF